Outlook Therapeutics/OTLK

$8.17

-1.44%
-
1D1W1MYTD1YMAX

About Outlook Therapeutics

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Ticker

OTLK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

C. Russell Trenary

Employees

24

Headquarters

Iselin, United States

OTLK Metrics

BasicAdvanced
$191.99M
Market cap
-
P/E ratio
-$3.99
EPS
0.30
Beta
-
Dividend rate
$191.99M
0.2971
$40.60
$4.00
643.83K
0.444
-122.07%
-441.62%
37.02%

What the Analysts think about OTLK

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
388.49% upside
High $60.00
Low $25.00
$8.17
Current price
$39.91
Average price target

OTLK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-
Net income
$-11.1M
-13.95%
Profit margin
0%
-

OTLK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.60
-$1.60
-$1.00
-$0.80
-
Expected
-$1.30
-$1.03
-$1.18
-$1.00
-$0.85
Surprise
-53.85%
55.56%
-14.89%
-20%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Outlook Therapeutics stock?

Outlook Therapeutics (OTLK) has a market cap of $191.99M as of April 20, 2024.

What is the P/E ratio for Outlook Therapeutics stock?

The price to earnings (P/E) ratio for Outlook Therapeutics (OTLK) stock is 0 as of April 20, 2024.

Does Outlook Therapeutics stock pay dividends?

No, Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Outlook Therapeutics dividend payment date?

Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders.

What is the beta indicator for Outlook Therapeutics?

Outlook Therapeutics (OTLK) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Outlook Therapeutics stock price target?

The target price for Outlook Therapeutics (OTLK) stock is $39.91, which is 388.49% above the current price of $8.17. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Outlook Therapeutics stock

Buy or sell Outlook Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing